Qiagen, the Dutch diagnostics company, has been granted SFDA approval for its careHPV Test. According to the company, the test is the first molecular diagnostic to screen for high-risk human papillomavirus (HPV) that is designed for resource-poor clinical settings – settings that lack electricity, water or a modern lab. The test can provide results during the patient’s visit. Qiagen will manufacture the test in its Shenzhen plant. More details.... Stock Symbol: (NSDQ: QGEN) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});